Effects of formoterol (Oxis (R) Turbuhaler (R)) and ipratropium on exercise capacity in patients with COPD
(2002) In Respiratory Medicine 96(8). p.559-566- Abstract
- Although long-acting inhaled beta(2)-agonists improve various outcome measures in COPD, no double-blind study has yet shown a significant effect of these drugs on exercise capacity. In a randomized, double-blind, placebo-controlled, crossover study, patients received formoterol (4.5,9, or 18 mug b.i.d via Turbuhaler(R)), ipratroplum bromide (80 mug t.i.d via pMDI with spacer), or placebo for I week. Main endpoint was time to exhaustion (TTE) in an incremental cycle ergometer test. Secondary endpoints were Borg dyspnoea score during exercise, lung function, and adverse events. Thirty-four patients with COPD were included, mean age 64.8 years, FEV(1)55.6% predicted, reversibility 6.1% predicted. All doses of formoterol, and ipratropium... (More)
- Although long-acting inhaled beta(2)-agonists improve various outcome measures in COPD, no double-blind study has yet shown a significant effect of these drugs on exercise capacity. In a randomized, double-blind, placebo-controlled, crossover study, patients received formoterol (4.5,9, or 18 mug b.i.d via Turbuhaler(R)), ipratroplum bromide (80 mug t.i.d via pMDI with spacer), or placebo for I week. Main endpoint was time to exhaustion (TTE) in an incremental cycle ergometer test. Secondary endpoints were Borg dyspnoea score during exercise, lung function, and adverse events. Thirty-four patients with COPD were included, mean age 64.8 years, FEV(1)55.6% predicted, reversibility 6.1% predicted. All doses of formoterol, and ipratropium significantly improved TTE, FEV1, FEF25-75%, FRC, IVC, RV and sGAW compared with placebo. A negative dose-response relationship was observed with formoterol. Ipratropium increased time to exhaustion more compared with formoterol, 18 mug, but not with formoterol, 4.5 and 9 mug. No changes in Borg score were found. There was no difference in the adverse event profile between treatments. In conclusion, I week of treatment with formoterol and ipratropium significantly improved exercise capacity and lung function compared with placebo. However, a negative dose-response relation for formoterol was unexpected and needs further investigation. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/331250
- author
- Liesker, JJW ; Van de Velde, V ; Meysman, M ; Vincken, W ; Wollmer, Per LU ; Hansson, Lennart LU ; Kerstjens, HAM ; Qvint, U and Pauwels, RA
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- exercise capacity, formoterol, COPD
- in
- Respiratory Medicine
- volume
- 96
- issue
- 8
- pages
- 559 - 566
- publisher
- Elsevier
- external identifiers
-
- wos:000177437700002
- pmid:12195835
- scopus:0036694823
- ISSN
- 1532-3064
- DOI
- 10.1053/rmed.2001.1335
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical Physiology (013242300), Respiratory Medicine and Allergology (013230111), Clinical Physiology and Nuclear Medicine Unit (013242320)
- id
- 019baa84-5f5b-461f-b901-d4c15d885e33 (old id 331250)
- date added to LUP
- 2016-04-01 16:30:36
- date last changed
- 2023-09-04 20:04:27
@article{019baa84-5f5b-461f-b901-d4c15d885e33, abstract = {{Although long-acting inhaled beta(2)-agonists improve various outcome measures in COPD, no double-blind study has yet shown a significant effect of these drugs on exercise capacity. In a randomized, double-blind, placebo-controlled, crossover study, patients received formoterol (4.5,9, or 18 mug b.i.d via Turbuhaler(R)), ipratroplum bromide (80 mug t.i.d via pMDI with spacer), or placebo for I week. Main endpoint was time to exhaustion (TTE) in an incremental cycle ergometer test. Secondary endpoints were Borg dyspnoea score during exercise, lung function, and adverse events. Thirty-four patients with COPD were included, mean age 64.8 years, FEV(1)55.6% predicted, reversibility 6.1% predicted. All doses of formoterol, and ipratropium significantly improved TTE, FEV1, FEF25-75%, FRC, IVC, RV and sGAW compared with placebo. A negative dose-response relationship was observed with formoterol. Ipratropium increased time to exhaustion more compared with formoterol, 18 mug, but not with formoterol, 4.5 and 9 mug. No changes in Borg score were found. There was no difference in the adverse event profile between treatments. In conclusion, I week of treatment with formoterol and ipratropium significantly improved exercise capacity and lung function compared with placebo. However, a negative dose-response relation for formoterol was unexpected and needs further investigation.}}, author = {{Liesker, JJW and Van de Velde, V and Meysman, M and Vincken, W and Wollmer, Per and Hansson, Lennart and Kerstjens, HAM and Qvint, U and Pauwels, RA}}, issn = {{1532-3064}}, keywords = {{exercise capacity; formoterol; COPD}}, language = {{eng}}, number = {{8}}, pages = {{559--566}}, publisher = {{Elsevier}}, series = {{Respiratory Medicine}}, title = {{Effects of formoterol (Oxis (R) Turbuhaler (R)) and ipratropium on exercise capacity in patients with COPD}}, url = {{http://dx.doi.org/10.1053/rmed.2001.1335}}, doi = {{10.1053/rmed.2001.1335}}, volume = {{96}}, year = {{2002}}, }